We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Analyst: Rituxan Warning Unlikely to Hurt Sales
Analyst: Rituxan Warning Unlikely to Hurt Sales
March 14, 2007
The FDA’s recent warning about serious adverse events involving off-label uses of Genentech’s drug Rituxan is unlikely to have a long-term financial impact on the company, a financial analyst says.